Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. / Sellebjerg, F; Börnsen, L; Khademi, M; Krakauer, M; Olsson, T; Frederiksen, J L; Sørensen, P S; Sellebjerg, F; Börnsen, L; Khademi, M; Krakauer, M; Olsson, T; Battistini, Jette Lautrup; Sørensen, Per Soelberg.

I: Neurology, Bind 73, Nr. 23, 2009, s. 2003-10.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Sellebjerg, F, Börnsen, L, Khademi, M, Krakauer, M, Olsson, T, Frederiksen, JL, Sørensen, PS, Sellebjerg, F, Börnsen, L, Khademi, M, Krakauer, M, Olsson, T, Battistini, JL & Sørensen, PS 2009, 'Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS', Neurology, bind 73, nr. 23, s. 2003-10. https://doi.org/10.1212/WNL.0b013e3181c5b457, https://doi.org/10.1212/WNL.0b013e3181c5b457

APA

Sellebjerg, F., Börnsen, L., Khademi, M., Krakauer, M., Olsson, T., Frederiksen, J. L., Sørensen, P. S., Sellebjerg, F., Börnsen, L., Khademi, M., Krakauer, M., Olsson, T., Battistini, J. L., & Sørensen, P. S. (2009). Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology, 73(23), 2003-10. https://doi.org/10.1212/WNL.0b013e3181c5b457, https://doi.org/10.1212/WNL.0b013e3181c5b457

Vancouver

Sellebjerg F, Börnsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL o.a. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009;73(23):2003-10. https://doi.org/10.1212/WNL.0b013e3181c5b457, https://doi.org/10.1212/WNL.0b013e3181c5b457

Author

Sellebjerg, F ; Börnsen, L ; Khademi, M ; Krakauer, M ; Olsson, T ; Frederiksen, J L ; Sørensen, P S ; Sellebjerg, F ; Börnsen, L ; Khademi, M ; Krakauer, M ; Olsson, T ; Battistini, Jette Lautrup ; Sørensen, Per Soelberg. / Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. I: Neurology. 2009 ; Bind 73, Nr. 23. s. 2003-10.

Bibtex

@article{4af17430a92b11df928f000ea68e967b,
title = "Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS",
abstract = "BACKGROUND: Accumulating evidence supports a major role of B cells in multiple sclerosis (MS) pathogenesis. How B cells are recruited to the CNS is incompletely understood. Our objective was to study B-cell chemokine concentrations in MS, their relationship with disease activity, and how treatment with methylprednisolone and natalizumab affected the concentration in CSF. METHODS: Using a cross-sectional design, CSF and blood samples were obtained from cohorts of patients with clinically isolated syndromes (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS), or secondary progressive MS (SPMS), and noninflammatory neurologic disease control subjects. Some patients with RRMS were studied before and after treatment with methylprednisolone or natalizumab. RESULTS: In CSF, concentrations of CXCL13, but not CXCL12, were higher in patients with CIS, RRMS, SPMS, and PPMS than in controls. CSF concentrations of CXCL13 correlated with the CSF B-cell count, with markers of immune activation, and with disease activity in patients with CIS and RRMS. CSF concentrations of CXCL13 decreased after treatment with high-dose methylprednisolone and natalizumab. High CSF concentrations of CXCL13 correlated with low expression of messenger RNA encoding the immunoregulatory cytokines interleukin 10 and transforming growth factor beta1, but not with the expression of T-helper type 1 (Th1) and Th17 factors. CONCLUSION: The chemokine CXCL13 may play a major role in recruitment of B cells and T-cell subsets expressing the chemokine receptor CXCR5 to the CNS in multiple sclerosis (MS), and may be a useful biomarker for treatment effects in MS. Furthermore, CXCL13 or its receptor CXCR5 should be considered as therapeutic targets in MS.",
author = "F Sellebjerg and L B{\"o}rnsen and M Khademi and M Krakauer and T Olsson and Frederiksen, {J L} and S{\o}rensen, {P S} and F Sellebjerg and L B{\"o}rnsen and M Khademi and M Krakauer and T Olsson and Battistini, {Jette Lautrup} and S{\o}rensen, {Per Soelberg}",
note = "Keywords: Adult; Aged; B-Lymphocytes; Biological Markers; Chemokine CXCL13; Cohort Studies; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Protein Transport; Receptors, CXCR5; T-Lymphocyte Subsets",
year = "2009",
doi = "10.1212/WNL.0b013e3181c5b457",
language = "English",
volume = "73",
pages = "2003--10",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams & Wilkins",
number = "23",

}

RIS

TY - JOUR

T1 - Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

AU - Sellebjerg, F

AU - Börnsen, L

AU - Khademi, M

AU - Krakauer, M

AU - Olsson, T

AU - Frederiksen, J L

AU - Sørensen, P S

AU - Sellebjerg, F

AU - Börnsen, L

AU - Khademi, M

AU - Krakauer, M

AU - Olsson, T

AU - Battistini, Jette Lautrup

AU - Sørensen, Per Soelberg

N1 - Keywords: Adult; Aged; B-Lymphocytes; Biological Markers; Chemokine CXCL13; Cohort Studies; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Protein Transport; Receptors, CXCR5; T-Lymphocyte Subsets

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Accumulating evidence supports a major role of B cells in multiple sclerosis (MS) pathogenesis. How B cells are recruited to the CNS is incompletely understood. Our objective was to study B-cell chemokine concentrations in MS, their relationship with disease activity, and how treatment with methylprednisolone and natalizumab affected the concentration in CSF. METHODS: Using a cross-sectional design, CSF and blood samples were obtained from cohorts of patients with clinically isolated syndromes (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS), or secondary progressive MS (SPMS), and noninflammatory neurologic disease control subjects. Some patients with RRMS were studied before and after treatment with methylprednisolone or natalizumab. RESULTS: In CSF, concentrations of CXCL13, but not CXCL12, were higher in patients with CIS, RRMS, SPMS, and PPMS than in controls. CSF concentrations of CXCL13 correlated with the CSF B-cell count, with markers of immune activation, and with disease activity in patients with CIS and RRMS. CSF concentrations of CXCL13 decreased after treatment with high-dose methylprednisolone and natalizumab. High CSF concentrations of CXCL13 correlated with low expression of messenger RNA encoding the immunoregulatory cytokines interleukin 10 and transforming growth factor beta1, but not with the expression of T-helper type 1 (Th1) and Th17 factors. CONCLUSION: The chemokine CXCL13 may play a major role in recruitment of B cells and T-cell subsets expressing the chemokine receptor CXCR5 to the CNS in multiple sclerosis (MS), and may be a useful biomarker for treatment effects in MS. Furthermore, CXCL13 or its receptor CXCR5 should be considered as therapeutic targets in MS.

AB - BACKGROUND: Accumulating evidence supports a major role of B cells in multiple sclerosis (MS) pathogenesis. How B cells are recruited to the CNS is incompletely understood. Our objective was to study B-cell chemokine concentrations in MS, their relationship with disease activity, and how treatment with methylprednisolone and natalizumab affected the concentration in CSF. METHODS: Using a cross-sectional design, CSF and blood samples were obtained from cohorts of patients with clinically isolated syndromes (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS), or secondary progressive MS (SPMS), and noninflammatory neurologic disease control subjects. Some patients with RRMS were studied before and after treatment with methylprednisolone or natalizumab. RESULTS: In CSF, concentrations of CXCL13, but not CXCL12, were higher in patients with CIS, RRMS, SPMS, and PPMS than in controls. CSF concentrations of CXCL13 correlated with the CSF B-cell count, with markers of immune activation, and with disease activity in patients with CIS and RRMS. CSF concentrations of CXCL13 decreased after treatment with high-dose methylprednisolone and natalizumab. High CSF concentrations of CXCL13 correlated with low expression of messenger RNA encoding the immunoregulatory cytokines interleukin 10 and transforming growth factor beta1, but not with the expression of T-helper type 1 (Th1) and Th17 factors. CONCLUSION: The chemokine CXCL13 may play a major role in recruitment of B cells and T-cell subsets expressing the chemokine receptor CXCR5 to the CNS in multiple sclerosis (MS), and may be a useful biomarker for treatment effects in MS. Furthermore, CXCL13 or its receptor CXCR5 should be considered as therapeutic targets in MS.

U2 - 10.1212/WNL.0b013e3181c5b457

DO - 10.1212/WNL.0b013e3181c5b457

M3 - Journal article

C2 - 19996075

VL - 73

SP - 2003

EP - 2010

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 23

ER -

ID: 21405985